Compare TSE & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSE | ASRT |
|---|---|---|
| Founded | 2010 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.0M | 75.1M |
| IPO Year | 2014 | 1997 |
| Metric | TSE | ASRT |
|---|---|---|
| Price | $0.56 | $0.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $1.00 | ★ $3.00 |
| AVG Volume (30 Days) | ★ 671.3K | 418.0K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | ★ 4.75% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,133,800,000.00 | $137,354,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.47 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 9.22 |
| 52 Week Low | $0.60 | $0.51 |
| 52 Week High | $6.85 | $1.01 |
| Indicator | TSE | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 26.08 | 42.19 |
| Support Level | $0.60 | $0.75 |
| Resistance Level | $0.76 | $0.80 |
| Average True Range (ATR) | 0.08 | 0.04 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 0.60 | 55.87 |
Trinseo PLC is a materials company and manufacturer of latex and plastics products. The company's operating segments include Latex Binders, Americas Styrenics, Engineered Materials, and Polymer Solutions. Maximum revenue is generated from its Polymer Solutions segment, which consists of various polymers, the majority of which are for automotive, building, and construction applications. The product offerings of this segment include ABS, styrene-acrylonitrile, polystyrene, and polycarbonate products, which are marketed through brands like Magnum and Styron. Geographically, the company generates maximum revenue from Europe, followed by the United States, Asia-Pacific, and the Rest of the world.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.